Determination of Metformin and Vildagliptin in Solid Dosage Form and Rabbit Plasma by HPLC: An Application to Pharmacokinetic Study

被引:0
作者
Shakoor, Abdul [1 ]
Ahmed, Mahmood [2 ]
Adnan, Ahmad [1 ]
Hussain, Riaz [3 ]
Hussain, Sajad [1 ]
Rehman, Kiren [1 ]
Rashid, Ayoub [1 ]
Mushtaq, Maria [1 ]
Batool, Sadia [4 ]
机构
[1] Govt Coll Univ, Dept Chem, Lahore, Pakistan
[2] Renacon Parma Ltd, Lahore 54600, Pakistan
[3] Univ Okara, Dept Chem, Okara, Pakistan
[4] King Khalid Univ, Coll Pharm, Abha, Saudi Arabia
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2019年 / 38卷 / 02期
关键词
diabetes mellitus; HPLC; metformin; pharmacokinetic; vildagliptin;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The present work aimed to validate a simple and rapid method for simultaneous determination of metformin hydrochloride (MTF) and vildagliptin (VLD) in tablet in addition to a pharmacokinetic study in rabbit plasma. Isocratic elution of both the analytes was performed at 35 degrees C by injecting 20 mu L into Thermo Hypersil ODS C18 column (5 mu m, 4.6 x 250 mm) while the flow rate was set to 0.8 mL/min. The mobile phase comprised of methanol, acetonitrile and phosphate buffer (5:30:65, v/v, pH 3.5) and wavelength was selected at 212 nm. The overall run time per sample was 7.0 min with retention time of 336 and 5.41 min for MTF and VLD, respectively. The calibration curve was linear from 10-140 mu g/mL for MTF and 1-14 mu g/mL for VLD with R-2 (coefficient of determination) <= 0.9919 while % RSD was less than 1.13 and 0.97 %, respectively, for repeatability and reproducibility. The proposed RP-HPLC method showed accuracy providing recoveries ranged between 100.13-100.29 %. For pharmacokinetic study, the proposed method successfully determined the MTF and VLD concentration in plasma after oral administration of both drugs to healthy and diabetic induced rabbits.
引用
收藏
页码:361 / 367
页数:7
相关论文
共 12 条
[1]   Stability Indicating UHPLC-PDA Assay for Simultaneous Determination of Antazoline Hydrochloride and Naphazoline Hydrochloride in Ophthalmic Formulations [J].
Ali, Amir ;
Farooq, Umar ;
Ahmed, Mahmood ;
Athar, Muhammad Makshoof ;
Nadeem, Kashif ;
Murtaza, Ghulam .
ACTA CHIMICA SLOVENICA, 2017, 64 (02) :332-341
[2]   Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: A retrospective analysis of the GALIANT study [J].
Banerji, M. A. ;
Purkayastha, D. ;
Francis, B. H. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 90 (02) :182-190
[3]   Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview [J].
Correia, Sonia ;
Carvalho, Cristina ;
Santos, Maria S. ;
Seica, Raquel ;
Oliveira, Catarina R. ;
Moreira, Paula I. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (13) :1343-1354
[4]  
Group I E.W., 2005, Proceedings of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, P25
[5]   Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin [J].
He, Yan-Ling .
CLINICAL PHARMACOKINETICS, 2012, 51 (03) :147-162
[6]  
Jehangir M., 2017, J ANAL METHODS CHEM, V2017, P9
[7]   Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis [J].
Karagiannis, Thomas ;
Paschos, Paschalis ;
Paletas, Konstantinos ;
Matthews, David R. ;
Tsapas, Apostolos .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 344 :17
[8]  
Modi D. K., 2013, J CHEM, V2013, P4
[9]  
Mohammad Mohammad Abdul-Azim., 2012, European Journal of Chemistry, V3, P152
[10]  
Santhosha B, 2012, Int. J. Pharm. Sci. Res., V2, P22